Protective effect of the inhibition of the renin-angiotensin system on aging

Nidia Basso1, Nora Paglia, Inés Stella

  • 1Laboratorio de Fisiopatología Cardiovascular, Departamento de Patología, Facultad de Medicina, Universidad de Buenos Aires, CONICET, Argentina.

Regulatory Peptides
|April 20, 2005
PubMed

Insights

Inhibiting the renin-angiotensin system (RAS) with enalapril or losartan protects against aging effects in rat cardiovascular and kidney systems. This intervention also improved brain function, suggesting RAS blockade delays aging by reducing oxidative stress.

Area of Science:

  • Gerontology and Cardiovascular Science
  • Nephrology and Neuroscience

Background:

  • Chronic inhibition of the renin-angiotensin system (RAS) shows promise in mitigating age-related decline.
  • Aging impacts cardiovascular, renal, and neurological functions, necessitating preventative strategies.

Purpose of the Study:

  • To review experimental evidence on the long-term effects of RAS inhibition on aging processes in rats.
  • To investigate the role of angiotensin II (AngII) in age-related cognitive and functional decline.

Main Methods:

  • Rats were treated with an ACE inhibitor (enalapril) or an AT1 receptor blocker (losartan) from weaning or at middle age.
  • Cardiovascular, kidney, and brain functions, including cognitive behavior, were assessed at various ages.
  • Mechanisms involving nitric oxide, antioxidant enzymes, and oxidative stress, particularly at the mitochondrial level, were analyzed.

Main Results:

  • RAS inhibition significantly protected cardiovascular, kidney, and brain structures and functions.
  • Treatment prevented further age-related deterioration, even when initiated at middle age.
  • Effects were largely mediated via AT1 receptors, suggesting a key role for AngII.

Conclusions:

  • Long-term RAS inhibition, particularly through AT1 receptor blockade, offers significant protection against age-related damage.
  • The protective effects are linked to reduced oxidative stress and improved mitochondrial function.
  • RAS inhibition may represent a therapeutic strategy to delay the aging process and its associated pathologies.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...